SAMD9 and esophageal squamous cell carcinoma: SAMD9 promotes MYH9/TRAF6‐regulated ubiquitination and degradation of GSK3β by binding to MYH9, leading to activation of the β‐catenin signaling pathway, which stimulates EMT, angiogenesis, and stemness of ESCC cells, and ultimately promotes ESCC metastasis and recurrence.